Aluminum Oxide Daphne Mezereum Bark Eclipta Prostr
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Aluminum Oxide Daphne Mezereum Bark Eclipta Prostr
- Homeopathic Multi-Component Combination (9 Ingredients): No Repurposing Prediction Available
Homeopathic Multi-Component Combination (9 Ingredients): No Repurposing Prediction Available
One-Sentence Summary
This drug is a nine-component combination — minerals (Graphite, Sulfur, Phosphorus, Thallium, Aluminum Oxide), plant-derived materials (Daphne Mezereum Bark, Eclipta Prostrata Whole, Lycopodium Clavatum Spore), and animal material (Sepia Officinalis Juice) — consistent with a classical homeopathic remedy composition, with no approved indication on record. The TxGNN model returned no repurposing predictions for this combination; no DrugBank ID or mechanism of action data could be identified. There is currently no evidence base to support a repurposing evaluation.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available |
| Predicted New Indication | None — TxGNN generated no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | Below L5 — no predictions, no studies |
| US Market Status | Not marketed in Taiwan |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
No safety data is available in standard pharmacological databases for this combination as a whole. Two individual components warrant attention:
- Thallium: A heavy metal with known systemic neurotoxicity; risk profile in combination formulations is uncharacterised.
- Daphne Mezereum Bark: Contains toxic diterpene esters (mezerein, daphnetoxin) with irritant and potentially mutagenic properties.
Please review individual component safety data and any applicable product label before proceeding.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN pipeline could not generate repurposing predictions for this combination because no DrugBank ID, approved indication, or mechanism of action data exists in accessible databases. Without these foundational inputs, neither mechanistic analysis nor evidence evaluation is possible.
To proceed, the following is needed:
- Confirm the regulatory category of this product (homeopathic medicine vs. conventional drug) and identify its country-of-origin approval status
- Obtain DrugBank entries or pharmacological data for each individual active component
- Re-run TxGNN using individual component DrugBank IDs to test whether any single ingredient yields a tractable repurposing signal
- Conduct a complete safety profile covering Thallium neurotoxicity and Daphne Mezereum phytotoxin exposure before any clinical consideration
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.